694507-52-3 Usage
Chemical class
Chromeno-pyrazole derivatives
Explanation
This compound belongs to a class of chemical compounds that are derived from the fusion of chromene and pyrazole rings.
Explanation
The molecule contains a carboxylic acid functional group, which is characterized by the presence of a carbonyl group (C=O) and a hydroxyl group (-OH) attached to the same carbon atom.
3. Potential pharmaceutical applications
Explanation
The compound has been studied for its potential use in the development of new drugs due to its unique structure and properties.
Explanation
Research has shown that 1,4-Dihydro-chromeno[4,3-c]pyrazole-3-carboxylic acid exhibits various biological activities, including the ability to inhibit viral replication, combat cancer cells, and act as an antioxidant.
Explanation
The compound is being investigated for its potential use as a building block in the synthesis of new drugs, which could lead to the development of more effective pharmaceuticals.
6. Promising candidate for pharmaceutical research
Explanation
The unique structure and properties of 1,4-Dihydro-chromeno[4,3-c]pyrazole-3-carboxylic acid make it a valuable candidate for further research in the field of pharmaceuticals, with the potential to contribute to the development of novel therapeutic agents.
Functional group
Carboxylic acid
Biological activities
Antiviral, anticancer, and antioxidant properties
Role in drug synthesis
Building block
Check Digit Verification of cas no
The CAS Registry Mumber 694507-52-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,4,5,0 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 694507-52:
(8*6)+(7*9)+(6*4)+(5*5)+(4*0)+(3*7)+(2*5)+(1*2)=193
193 % 10 = 3
So 694507-52-3 is a valid CAS Registry Number.
694507-52-3Relevant articles and documents
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Chianelli, Donatella,Rucker, Paul V.,Roland, Jason,Tully, David C.,Nelson, John,Liu, Xiaodong,Bursulaya, Badry,Hernandez, Eloy D.,Wu, Jane,Prashad, Mahavir,Schlama, Thierry,Liu, Yugang,Chu, Alan,Schmeits, James,Huang, David J.,Hill, Robert,Bao, Dingjiu,Zoll, Jocelyn,Kim, Young,Groessl, Todd,McNamara, Peter,Liu, Bo,Richmond, Wendy,Sancho-Martinez, Ignacio,Phimister, Andrew,Seidel, H. Martin,Badman, Michael K.,Joseph, Sean B.,Laffitte, Bryan,Molteni, Valentina
supporting information, p. 3868 - 3880 (2020/05/27)
Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for the treatment of nonalcoholic steatohepatitis (NASH) patients, as they exert positive effects on multiple aspects of the disease. FXR agonists reduce lipid accumulation in the liver, hepatocellular inflammation, hepatic injury, and fibrosis. While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. Previously, we described the discovery of tropifexor (LJN452), the most potent non-bile acid FXR agonist currently in clinical investigation. Here, we report the discovery of a novel chemical series of non-bile acid FXR agonists based on a tricyclic dihydrochromenopyrazole core from which emerged nidufexor (LMB763), a compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase 2 human clinical trials in patients with NASH and diabetic nephropathy.
